ANDARINE S4 SARM Solution 50mg/ml – 50ml

ANDARINE S4 SARM Solution 50mg/ml – 50ml

What Is Andarine (S4)?

Andarine (S4, GTx-007) is a non-steroidal partial agonist at the androgen receptor developed by GTX Inc. as part of the same research program that produced Ostarine. While structurally related to MK-2866 (Ostarine), Andarine binds the AR with higher affinity and demonstrates greater anabolic potency per unit dose — but at a cost: it is the only SARM known to cause a distinctive transient visual disturbance characterized by a yellowish tint to vision and difficulty adapting to low-light conditions. This effect arises from partial AR agonism in retinal and lens tissue and makes Andarine uniquely interesting for ocular androgen receptor research.

Mechanism of Action

Andarine acts as a tissue-selective partial agonist — producing anabolic effects in muscle and bone while eliciting partial agonism in reproductive tissues and the retina. Its binding affinity for the AR (Ki ~4 nM) is higher than Ostarine but lower than full agonists like LGD-4033 or RAD-140. The higher concentration required for full receptor occupancy, combined with its shorter half-life (requiring more frequent dosing in animal studies), partially offsets its greater intrinsic activity relative to Ostarine in practical research designs.

Research Applications

• AR selectivity studies: Andarine’s ocular AR activity makes it a unique tool for studying receptor expression in non-musculoskeletal tissue.
• Bone density research: Demonstrates dose-dependent bone formation effects with less prostate stimulation than testosterone.
• SARM panel studies: Standard component of comprehensive AR selectivity panels alongside Ostarine, RAD-140, and LGD-4033.

Related Compounds

Andarine is typically studied alongside MK-2866 (Ostarine) in comparative SARM designs. See our guide: Ostarine vs Andarine (S4): SARM Selectivity in Research. Also available in powder format: Andarine (S4) Powder (1g).

For laboratory research use only.